NEW YORK (GenomeWeb) – Startup Bluestar Genomics, a spinout of the Stephen Quake lab at Stanford University, has uncovered a link between an epigenomic signal in cell-free DNA (cfDNA) and pancreatic cancer in patients.

Based on its findings, Bluestar is developing a non-invasive liquid biopsy assay that tracks epigenetic modifications linked to gene regulation and pancreatic cancer pathogenesis in circulating cfDNA in patient blood samples.  

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.